Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.60 |
| ▸ | CDK4 | P11802 | 3/20 | 0.54 |
| ▸ | CCND1 | P24385 | 3/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6554484 | 0.89 | PARP1 (0.66) | PARP1KCNH2PARP2 | |
| Hydrochloric Acid SCHEMBL6404360 | 0.88 | PARP1 (0.65) | PARP1KCNH2PARP2 | |
| SCHEMBL31061696 | 0.87 | PARP1 (1.00) | PARP1KCNH2PARP2CDK4CCND1 | |
| Hydrochloric Acid SCHEMBL6406540 | 0.86 | PARP1 (0.97) | PARP1KCNH2PARP2CDK4CCND1 | |
| SCHEMBL6554247 | 0.85 | PARP1 (0.74) | PARP1KCNH2PARP2 | |
| Hydrochloric Acid SCHEMBL6403910 | 0.84 | PARP1 (0.72) | PARP1KCNH2PARP2 | |
| Hydrochloric Acid SCHEMBL6408278 | 0.82 | PARP1 (0.66) | PARP1KCNH2PARP2KDM4EALDH1A1 | |
| SCHEMBL6404621 | 0.81 | PARP1 (0.68) | PARP1KCNH2PARP2KDM4E | |
| Hydrochloric Acid SCHEMBL6404822 | 0.80 | PARP1 (0.64) | PARP1KCNH2PARP2 | |
| Hydrochloric Acid SCHEMBL6554788 | 0.80 | PARP1 (0.67) | PARP1KCNH2PARP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1487800-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080581-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | PARP1, PARP11, PARP2 | PARP1 1/4885KCNH2 2357/4885PARP2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.